Key Details
Last Dividend
$0.67Annual Revenue
$150.79 MAnnual EPS
-$1.17Annual ROE
37.16%Beta
-Events Calendar
Next earnings date:
N/ARecent quarterly earnings:
Nov 03, 2023Recent annual earnings:
Mar 16, 2023Next ex-dividend date:
N/ARecent ex-dividend date:
Oct 31, 2014Next split:
N/ARecent split:
Oct 31, 2014Analyst ratings
Recent major analysts updates
07 Aug '23 HC Wainwright & Co.
Neutral10 July '23 HC Wainwright & Co.
Neutral07 June '23 Jefferies
Hold07 June '23 HC Wainwright & Co.
Neutral20 Mar '23 HC Wainwright & Co.
Buy06 May '22 HC Wainwright & Co.
Buy17 Mar '22 HC Wainwright & Co.
Buy10 Feb '22 WBB Securities
Strong Buy09 Nov '21 HC Wainwright & Co.
Buy21 June '21 HC Wainwright & Co.
BuyScreeners with PRTK included
No data
Market Data
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Dividend
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Profitability
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Efficiency
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Valuation
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Liquidity
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Cash Flow
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Institutional Ownership
Similar stocks
Paratek Pharmaceuticals Announces Presentation of Several New Studies of NUZYRA® (omadacycline) Across a Range of Serious Infections at IDWeek 2024
PRTK
globenewswire.com14 October 2024
-- Highlights include data from clinical, non-clinical and microbiology programs, real-world patient use and a five-year microbiologic surveillance study of NUZYRA BOSTON, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc., a biopharmaceutical company focused on providing innovative medical therapies that create positive patient stories in the hospital, community and public health settings, announces that data from several new studies of NUZYRA® (omadacycline) will be presented at IDWeek 2024, Oct. 16-19 at the Los Angeles Convention Center in Los Angeles, CA. “We continue to invest in science as part of our continued commitment to furthering the medical community's understanding of NUZYRA's potential utility across a broad range of serious, community-acquired infections, including pulmonary and skin infections,” said Randy Brenner, chief development and regulatory officer of Paratek.
FAQ
- What is the primary business of Paratek Pharmaceuticals?
- What is the ticker symbol for Paratek Pharmaceuticals?
- Does Paratek Pharmaceuticals pay dividends?
- What sector is Paratek Pharmaceuticals in?
- What industry is Paratek Pharmaceuticals in?
- What country is Paratek Pharmaceuticals based in?
- When did Paratek Pharmaceuticals go public?
- Is Paratek Pharmaceuticals in the S&P 500?
- Is Paratek Pharmaceuticals in the NASDAQ 100?
- Is Paratek Pharmaceuticals in the Dow Jones?
- When was Paratek Pharmaceuticals's last earnings report?
- When does Paratek Pharmaceuticals report earnings?
- Should I buy Paratek Pharmaceuticals stock now?
What is the primary business of Paratek Pharmaceuticals?
Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its products include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia, and acute skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a once-daily oral therapy for the treatment of moderate to severe acne vulgaris. The company has license and collaboration agreements with Zai Lab (Shanghai) Co., Ltd. and Allergan plc; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and contract with Biomedical Advanced Research and Development Authority to support the development of NUZYRA for the treatment of pulmonary anthrax. It also has license agreement with Tetraphase Pharmaceuticals, Inc. to develop, import, and sell the XERAVATM product, which is used for the treatment of complicated intra-abdominal infections caused by bacteria. The company was founded in 1996 and is headquartered in Boston, Massachusetts.
What is the ticker symbol for Paratek Pharmaceuticals?
The ticker symbol for Paratek Pharmaceuticals is NASDAQ:PRTK
Does Paratek Pharmaceuticals pay dividends?
No, Paratek Pharmaceuticals does not pay dividends
What sector is Paratek Pharmaceuticals in?
Paratek Pharmaceuticals is in the Healthcare sector
What industry is Paratek Pharmaceuticals in?
Paratek Pharmaceuticals is in the Biotechnology industry
What country is Paratek Pharmaceuticals based in?
Paratek Pharmaceuticals is headquartered in United States
When did Paratek Pharmaceuticals go public?
Paratek Pharmaceuticals's initial public offering (IPO) was on 03 February 2009
Is Paratek Pharmaceuticals in the S&P 500?
No, Paratek Pharmaceuticals is not included in the S&P 500 index
Is Paratek Pharmaceuticals in the NASDAQ 100?
No, Paratek Pharmaceuticals is not included in the NASDAQ 100 index
Is Paratek Pharmaceuticals in the Dow Jones?
No, Paratek Pharmaceuticals is not included in the Dow Jones index
When was Paratek Pharmaceuticals's last earnings report?
Paratek Pharmaceuticals's most recent earnings report was on 3 November 2023
When does Paratek Pharmaceuticals report earnings?
The date for Paratek Pharmaceuticals's next earnings report has not been announced yet
Should I buy Paratek Pharmaceuticals stock now?
As of today, analysts generally recommend a 'Hold' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions